首页 › 非小细胞肺癌 › 宾夕法尼亚州 › Allentown
Allentown PA 非小细胞肺癌临床试验
14项针对 非小细胞肺癌的研究正在 Allentown及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
招募中1/2 期
- Spoknwrd Clinical Trials /ID# 273776, Easton · 距离 15 英里
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem · 距离 6 英里
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- St. Lukes Hospital and Health Network ( Site 0186), Bethlehem · 距离 6 英里
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem · 距离 6 英里
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
招募中3 期
- Alliance Cancer Specialists, Sellersville · 距离 20 英里
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- Alliance Cancer Specialists, PC, Sellersville · 距离 20 英里
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
招募中3 期
- Research Site, Fountain Hill · 距离 5 英里
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
招募中2 期
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem · 距离 6 英里
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
招募中3 期
- Local Institution - 0688, Easton · 距离 15 英里
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
招募中3 期
- St. Luke's University Health Network, Bethlehem · 距离 6 英里
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
招募中3 期
- St Luke's University Health Network ( Site 0017), Bethlehem · 距离 6 英里
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Lehigh Valley Health Network (Data Collection Only), Allentown
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中观察性研究
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem · 距离 6 英里
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
招募中2 期
- Lehigh Valley Health Network, Allentown
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Allentown的其他研究
- 乳腺癌10 项研究
- 急性髓系白血病8 项研究
- 结直肠癌7 项研究
- 肺癌7 项研究
- 黑色素瘤6 项研究
- 癌症（所有类型）6 项研究
- 重度抑郁症6 项研究
- 冠状动脉疾病5 项研究
- 伯基特淋巴瘤5 项研究
- 卵巢癌5 项研究
- 结肠癌5 项研究
- 直肠癌5 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。